📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Chondroitin Sulfate Proteoglycan 4 (CSPG4) as an Emerging Target for Immunotherapy to Treat Melanoma. (2024)

First Author: Chen X

Attributed to: The impact of antibody isotype on patient monocyte and macrophage functions and activation states to manipulate anti-tumour responses in melanoma funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.3390/cancers16193260

PubMed Identifier: 39409881

Publication URI: http://europepmc.org/abstract/MED/39409881

Type: Journal Article/Review

Volume: 16

Parent Publication: Cancers

Issue: 19

ISSN: 2072-6694